Evidence map›Paper›PMID 41743503›Full record

ArticleCurrent research in structural biology2026

Screening for novel chemical scaffolds targeting PCNA identifies the Hsp90alpha inhibitor SNX-2112.

Jennifer Jossart, Ning Ma, Pouya Haratipour, Caroline M Li, Christopher Jang, Long Gu, Terrence E O'Brien, Nagarajan Vaidehi, Linda H Malkas, Robert J Hickey and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current research in structural biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer JossartDepartment of Cancer Biology and Molecular Medicine, City of Hope Medical Center, Monrovia, CA, USA.
Ning MaDepartment of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA, 91010, USA.
Pouya HaratipourDepartment of Cancer Biology and Molecular Medicine, City of Hope Medical Center, Monrovia, CA, USA.
Caroline M LiDepartment of Molecular Diagnostics and Experimental Therapeutics, City of Hope Medical Center, Monrovia, CA, USA.
Christopher JangDepartment of Molecular Diagnostics and Experimental Therapeutics, City of Hope Medical Center, Monrovia, CA, USA.
Long GuDepartment of Molecular Diagnostics and Experimental Therapeutics, City of Hope Medical Center, Monrovia, CA, USA.
Terrence E O'BrienAtomwise, Inc. San Francisco, CA, USA.
Nagarajan VaidehiDepartment of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA, 91010, USA.
Linda H MalkasDepartment of Molecular Diagnostics and Experimental Therapeutics, City of Hope Medical Center, Monrovia, CA, USA.
Robert J HickeyDepartment of Cancer Biology and Molecular Medicine, City of Hope Medical Center, Monrovia, CA, USA.
J Jefferson P PerryDepartment of Cancer Biology and Molecular Medicine, City of Hope Medical Center, Monrovia, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proliferating cell nuclear antigen (PCNA) protein is an emerging therapeutic target for several diseases including cancers, and certain viral infections. It was previously regarded as being undruggable, due to its functions as a molecular hub that regulates a multitude of essential cellular pathways. However, we recently developed a PCNA inhibitor, AOH1996, which acts as a molecular glue between PCNA and RNA Pol II promoting selective killing of cancer cells through the induction of transcription-replication conflicts. We have now moved this investigational new drug into Phase 1 clinical trials. Yet, the discovery of new PCNA inhibitors is still of notable importance, because of the potential for further improving the potency and overall

Identifiers

PMID41743503
PMCPMC12930076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.